05/28/2025 13:00
AVEDA Launches in the U.S. Amazon Premium Beauty Store

AVEDA, a purpose-driven pioneer of plant-powered, high-performance beauty announces its debut in the U.S. Amazon Premium Beauty store, bringing its assortment of vegan hair, skin, body and lifestyle products to new consumers across the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528898881/en/ “With the launch of AVEDA in the U.S. Amazon Premium Beauty store, we’re not only introducing more people to the world of AVEDA...

06/03/2025 07:35
BELFOR Highlights Digital Transformation in Damage Assessment at Asia Claims Convention 2025 in Osaka

BELFOR, the world’s leading provider of disaster recovery and property restoration services, recently participated in the Asia Claims Convention 2025, held from 13 to 15 May 2025 in Osaka, Japan. The event brought together 231 attendees representing 103 companies from across the insurance, risk management and restoration industries. At the heart of BELFOR’s contribution was a compelling presentation by Mr. Guido Gavio, Asia Complex Loss Director, titled “How Digital Transformation Is Reshapin...

06/03/2025 08:00
Storm Reply and Audi Set New Standards for Cloud Management with Agentic AI

Storm Reply, the Reply Group company specialising in innovative cloud-based solutions and services, is supporting Audi’s Cloud Foundation Services team in enhancing its cloud management activities through the introduction of Devbot, a digital assistant powered by Agentic AI technologies. Designed to optimise the use of cloud infrastructure, Devbot automates the handling of recurring support requests. Preparing to deploy a system where Audi employees receive personalized recommendations in real ...

05/17/2025 06:58
Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with am...